BRAF and melanoma: Together, these data show that BMP-2, nodal and their respective antagonists neither influence melanoma cell proliferation nor sensitize melanoma cells for the current standard treatment regimen for BRAF-mutated metastatic melanoma patients (BRAF±MEK-inhibition).